| 袁春晓,刘晓龙,段洪波,等.芪参还五胶囊治疗帕金森病 45例疗效观察[J].安徽医药,2023,27(10):2099-2102. |
| 芪参还五胶囊治疗帕金森病 45例疗效观察 |
| Clinical effect of Qishen Huanwu capsule on 45 cases of Parkinson's disease |
| |
| DOI：10.3969/j.issn.1009-6469.2023.10.041 |
| 中文关键词: 帕金森病 芪参还五胶囊 多巴丝肼 中医症候积分 胱抑素 -C |
| 英文关键词: Parkinson disease Qishen Huanwu capsule Dopasrazide TCM syndrome score Cystatin-C |
| 基金项目:河北省中医药管理局资助项目( 2021295) |
|
| 摘要点击次数: 720 |
| 全文下载次数: 380 |
| 中文摘要: |
| 目的探讨芪参还五胶囊对帕金森病病人的治疗效果。方法选取 2019年 8月至 2021年 8月河北省沧州中西医结合医院接收的 90例帕金森病病人，采用随机数字表法随机分为中西医结合组( 45例)和西药组( 45例)西药组给予多巴丝肼治疗，中西医结合组给予芪参还五胶囊联合多巴丝肼治疗，比较两组病人中医证候积分、统一帕金森病评，分量表( unified Parkinson′s disease rating scale，UPDRS)评分、血清胱抑素 -C(Cystatin C，Cysc)、同型半胱氨酸( homocysteine，Hcy)、神经营养因子 -3(neurotrophin-3，NT-3)水平、氧化应激指标 -丙二醛( malonaldehyde，MDA)、超氧化物歧化酶(superoxide dismutase，SOD)、8-羟基脱氧尿苷酸( 8-hydroxydeoxyguanosine，8-OHdG)水平，霍恩 -雅尔( Hoehn-Yahr)分级评估病人肢体功能。结果中西医结合组病人各项中医证候积分［步态摇曳( 0.38±0.11比 0.22±0.06)、肢体震颤( 0.33±0.09比 0.16±0.05)、言语謇涩( 0.49±0.13比 0.36±0.10)、肢体拘挛( 0.42±0.13比 0.22±0.07)、便秘( 0.63±0.18比 0.29±0.08)］、 UPDRS评分( 11.46±3.72比 5.25±1.69)分及血清 Cysc(0.14±0.04比 0.05±0.01)、 Hcy(9.34±2.39比 4.26±1.10)、 NT-3(15.40±3.93比 6.06±1.54)、 MDA(5.33±1.36比 2.87±0.75)、 SOD(27.47±6.90比 11.25±2.89)kU/L、8-OHdG(14.67±3.71比 8.31±2.12)水平治疗前后差值均较西药组大( P<0.05)；治疗后，中西医结合组病人 Hoehn-Yahr分级为 Ⅰ级、 Ⅱ级人数明显多于西药组， Ⅲ级、 Ⅳ级、 Ⅴ级人数明显少于西药组( P<0.05)。结论芪参还五胶囊联合多巴丝肼用于帕金森病病人，能够改善病人中医证候及肢体运动功能，促进神经系统修复及降低病人氧化应激损伤水平，效果较好。 |
| 英文摘要: |
| Objective To investigate the therapeutic effect of Qishen Huanwu capsule on Parkinson′s disease.Methods Ninety patients with Parkinson′s disease admitted to Cangzhou Hospital of Integrated Traditional and Western Medicine in Hebei Province fromAugust 2019 to August 2021 were randomly selected and randomly assigned into integrated traditional chinese and western medicinegroup (45 cases) and western medicine group (45 cases) using a random number table. The western medicine group was treated with dopaserizide, while the integrated traditional chinese and western medicine group was treated with Qishen Huanwu capsules combinedwith dopaserizide treatment. The TCM syndrome scores, unified Parkinson′s disease rating scale (UPDRS) score, serum Cystatin C(Cysc), homocysteine (Hcy), neurotrophin-3 (NT-3) level, oxidative stress indicators-malonaldehyde (MDA), superoxide dismutase (SOD), and 8-hydroxydeoxyguanosine (8-OHdG)] levels were compared among patients in the two groups, and the limb function of patients was evaluated by Hoehn-Yahr classification.Results The differences of TCM syndrome scores [Gait swaying (0.38 ± 0.11 vs. 0.22±0.06), limb tremors (0.33±0.09 vs. 0.16±0.05), awkward speech (0.49±0.13 vs. 0.36±0.10), limb cramps (0.42±0.13 vs. 0.22± 0.07), constipation (0.63±0.18 vs. 0.29±0.08)], UPDRS scores (11.46±3.72 vs. 5.25±1.69) and serum Cysc (0.14±0.04 vs. 0.05±0.01), Hcy (9.34±2.39 vs. 4.26±1.10), NT-3 (15.40±3.93 vs. 6.06±1.54), MDA (5.33±1.36 vs. 2.87±0.75), SOD (27.47±6.90 vs. 11.25±2.89) kU/L and 8-OHdG(14.67±3.71 vs. 8.31±2.12) levels in integrated chinese and western medicine group before and after treatment werelarger than those in western medicine group (P<0.05); after treatment, the numbers of patients with Hoehn-Yahr grade I and Ⅱ in theintegrated traditional chinese and western medicine group were significantly higher than those of the western medicine group, and thenumbers of patients in grade Ⅲ , Ⅳ , and Ⅴ were significantly less than those of the western medicine group (P<0.05).Conclusion Qishen Huanwu capsule combined with dopasrazide for patients with Parkinson′s disease can improve TCM syndromes and limb motorfunction, promote the repair of nervous system and reduce the level of oxidative stress injury. The effect is better. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
